Therapeutic potential of dendritic cell vaccines in sarcoma of the extremities
/in Dendritic Cells, International Publications, Soft Tissue Sarcoma /von 2009-08-01 / Expert Rev Anticancer Ther 2009 Aug;9(8):1065-71Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens
/in Dendritic Cells, Glioblastoma, International Publications /von 2009-08-01 / Stem Cells 2009 Aug;27(8):1734-40Killer dendritic cells and their potential for cancer immunotherapy
/in Dendritic Cells, International Publications /von 2009-07-18 / Cancer Immunol. Immunother. 2010 Jan;59(1):1-11Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice
/in Dendritic Cells, International Publications /von 2009-07-07 / Clin. Cancer Res. 2009 Jul;15(14):4612-21Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendritic cells for dendritic cell-based immunotherapy
/in Dendritic Cells, International Publications /von 2009-07-01 / J. Immunother. 2009 Jul-Aug;32(6):638-54Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2009-07-01 / J. Intern. Med. 2009 Jul;266(1):99-113Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10
/in Dendritic Cells, HIV/AIDS, International Publications /von 2009-06-15 / J. Infect. Dis. 2009 Jun;199(12):1862-71Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer
/in Dendritic Cells, International Publications, Malignant Melanoma, Prostate Cancer /von 2009-06-15 / Prostate 2009 Jun;69(9):938-48Cellular immunotherapy for ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2009-06-01 / Expert Opin Biol Ther 2009 Jun;9(6):677-88
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de